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Abstract
Background: Intervention-generated inequalities are unintended variations in outcome that result from the organisation
and delivery of health interventions. Socioeconomic inequalities in treatment may occur for some common cancers.
Although the incidence and outcome of lung cancer varies with socioeconomic position (SEP), it is not known whether
socioeconomic inequalities in treatment occur and how these might affect mortality. We conducted a systematic review and
meta-analysis of existing research on socioeconomic inequalities in receipt of treatment for lung cancer.
Methods and Findings: MEDLINE, EMBASE, and Scopus were searched up to September 2012 for cohort studies of
participants with a primary diagnosis of lung cancer (ICD10 C33 or C34), where the outcome was receipt of treatment (rates or
odds of receiving treatment) and where the outcome was reported by a measure of SEP. Forty-six papers met the inclusion
criteria, and 23 of these papers were included in meta-analysis. Socioeconomic inequalities in receipt of lung cancer treatment
were observed. Lower SEP was associated with a reduced likelihood of receiving any treatment (odds ratio [OR] = 0.79 [95% CI
0.73 to 0.86], p,0.001), surgery (OR= 0.68 [CI 0.63 to 0.75], p,0.001) and chemotherapy (OR=0.82 [95% CI 0.72 to 0.93],
p = 0.003), but not radiotherapy (OR= 0.99 [95% CI 0.86 to 1.14], p = 0.89), for lung cancer. The association remained when
stage was taken into account for receipt of surgery, and was found in both universal and non-universal health care systems.
Conclusions: Patients with lung cancer living in more socioeconomically deprived circumstances are less likely to receive any
type of treatment, surgery, and chemotherapy. These inequalities cannot be accounted for by socioeconomic differences in
stage at presentation or by differences in health care system. Further investigation is required to determine the patient,
tumour, clinician, and system factors that may contribute to socioeconomic inequalities in receipt of lung cancer treatment.
Please see later in the article for the Editors’ Summary.
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Introduction
Lung cancer is the most commonly occurring cancer worldwide.
In the USA and the UK it is the second most incident cancer [1,2],
as well as the most common cause of cancer mortality [2,3].
Survival differs internationally. In the UK, fewer than 10% of
those diagnosed with lung cancer survive for 5 years [3,4], with
higher survival rates found in Nordic countries [4,5], the USA
[2,5], Australia, and Canada [4].
Lung cancers are classified into small cell (SCLC) and non-small
cell (NSCLC) lung cancers. NSCLC is more common than SCLC
and has a better survival rate [6]. National Institute for Health and
Clinical Excellence (NICE) guidelines recommend radical surgery
for stage I or II NSCLC [6]. Chemotherapy and radiotherapy are
Figure 1. Flow diagram of study selection and exclusion. CI, confidence interval; SEP, socioeconomic position.
doi:10.1371/journal.pmed.1001376.g001
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recommended for later-stage NSCLC patients and are the
treatments of choice for SCLC [6]. Treatment intervention with
surgery, chemotherapy, or radiotherapy has been shown to
improve lung cancer survival [6].
Socioeconomic inequalities in incidence of, and survival from,
the majority of cancers have been reported [1,3,7]. A recent non-
systematic review revealed socioeconomic inequalities in receipt of
treatment for colorectal cancer [8], and it has been suggested that
socioeconomic differences in access to treatment might at least
partially explain socioeconomic differences in survival [9].
Unintended variations in outcome that result from the way that
health interventions are organised and delivered have been
described as intervention-generated inequalities [10].
Incidence of lung cancer is higher [1,11], and survival poorer
[7], in the most deprived patient groups. However, it is not known
whether socioeconomic inequalities in receipt of treatment exist
for lung cancer and, if so, what contribution they make to overall
socioeconomic inequalities in outcome. In order to explore the first
of these questions, we undertook a systematic review and meta-
analysis of cohort studies examining the association between
socioeconomic position (SEP) and receipt of lung cancer
treatment.
Methods
A protocol (see Text S2) was developed and systematic methods
were used to identify relevant studies, assess study eligibility for
inclusion, and evaluate study quality. The review is reported
according to the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) guidelines [12] (see Text
S1 for PRISMA checklist).
Literature Search
The online databases of MEDLINE and EMBASE were
searched up to September 2012 (see Table S1 for full search
strategies). No language restriction was applied. A search of
Scopus uncovered no further papers. Additional studies were
identified by reviewing the reference lists of all included studies
and by using a forward citation search to identify more recent
studies that had cited included studies. EndNote X5 software was
used to manage the references.
Study Eligibility
Studies that met the following criteria were included in the
review: primary, cohort studies of participants with a primary
diagnosis of lung cancer (ICD10 C33 or C34) reported separately
from other cancers; published in a peer-reviewed journal; where at
least one reported outcome was receipt of treatment (measured by
rates or odds of receiving treatment); and where receipt of this
outcome was reported by a measure of SEP. Any curative or
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apy, and radiotherapy was included.
Studies where SEP was included as a descriptive variable or
confounder, but where outcomes for receipt of treatment by SEP
were not presented, were not eligible for inclusion, but the authors
were contacted to determine whether relevant data were available
that might allow for inclusion in the review.
Studies where multivariable analysis was conducted (and
included control for a minimum of age and sex as confounders);
receipt of treatment was compared to not receiving treatment;
odds ratios (ORs) and 95% confidence intervals (CIs) of receipt of
treatment in low compared to high SEP were calculated; and SEP
was not further stratified by another variable, were considered
suitable for inclusion in meta-analysis.
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Acceptable measures of SEP were: area-based indices of
deprivation (e.g., Index of Multiple Deprivation [IMD], Town-
send Score, Carstairs Index); and area or individual measures of
income, poverty, or education level.
Multiple papers using the same or overlapping study data were
included. Sensitivity analyses were conducted including all eligible
papers and using different combinations of included papers, but
only data from the better quality or more detailed paper in each
overlapping study group were included in the final meta-analyses.
Sensitivity meta-analyses are included in the supplemental material.
Study Selection and Data Extraction
Studies obtained from the database searches were independent-
ly assessed by two researchers (LFF and HW) in three phases: title,
abstract, and full paper screening. Any disagreements at any of the
screening stages were resolved by discussion between the two
researchers in the first instance and with a third reviewer (JA) if
agreement could not be reached. Data extraction was carried out
by LFF using an Access database pro-forma developed for this
purpose, and double-checked by HW.
There is evidence to suggest that health insurance status is an
important factor relating to access to lung cancer care in countries
such as the USA that rely on insurance-based health care systems
[13]. Insurance status is less relevant and rarely measured in most
other countries. Therefore, three analytical categories were
developed a priori: studies conducted in a universal health care
system (UHCS), free at the point of access (similar to the UK);
studies conducted in countries with primarily private insurance
health care systems (non-UHCS, similar to the USA) [14]; and
studies conducted in countries with social insurance health care
systems (similar to many European countries). No studies were
identified that fell into the third category.
Study Quality
A study quality tool, adapted from existing quality tools [15,16],
was used to divide studies into six quality categories, with 1 being
the lowest, and 6 the highest, quality (see Text S3). Quality
assessment was carried out by LFF and checked by HW.
Cohort studies reporting only univariable analysis are of lower
quality in terms of their ability to control for confounding. Only
studies conducting multivariable analysis (quality scores 3–6) were
included in the meta-analysis. All studies that met the inclusion
criteria were analysed in the narrative synthesis.
Statistical Analysis
Trends in receipt of treatment across SEP groups were
described in the narrative analysis of all studies that met the
inclusion criteria.
Meta-analysis of eligible studies was undertaken using Cochrane
Collaboration Review Manager 5.1. Natural logs of the ORs and
their standard errors (SEs) were calculated for use in forest plots.
Random-effects meta-analysis of the odds of treatment in the
lowest compared to the highest SEP group was conducted. Where
a study reported the most deprived class as the comparator,
reverse ORs were calculated. Studies that presented a single OR
as either an OR for a one unit increase in deprivation score or
incremental quintile increase in income were not included.
Subgroup analyses by treatment type and health care system
were conducted. In meta-analyses where a ‘‘substantial’’ percent-
age [17] of the variability appeared to be due to the heterogeneity
of the studies rather than to chance, further subgroup analyses by
stage, histology, and quality score were conducted, where
appropriate, in order to examine potential sources of heterogene-
ity. A funnel plot was used to assess potential publication bias.
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Results
Included Papers/Studies
A total of 46 papers met the inclusion criteria and were included
in the review (see the PRISMA flow diagram [Figure 1]). Twenty-
eight papers were from UHCS countries (Tables 1 and 2). Of
these, 19 UK papers examined 13 study populations, although as
these included national and regional populations from different
sources, there was some further population overlap. One UK
paper also compared treatment in Scotland and Canada [18]. A
further nine papers from Canada (2), Sweden (1), Australia (1),
Italy (1), France (1), and New Zealand (3) were included. The three
New Zealand papers all examined the same population.
Eighteen papers were from non-UHCSs, all of which were from
the USA (Tables 3 and 4). The majority of non-UHCS papers
used sub-groups of the National Cancer Institute’s Surveillance,
Epidemiology and End Results (SEER) database population and,
again, some population overlap was found.
An individual measure of SEP (education level) was used in one
study [19]. All other studies used area-level measures of
deprivation, income, poverty, or education level.
In terms of quality, the non-UHCS studies that carried out
multivariable analyses had better control for confounding than did
UHCS studies, as they tended to stratify by stage and histology.
However, half of the non-UHCS papers used a Medicare-only
population aged over 65, and so were more restrictive in
population terms than the UHCS studies.
Twenty-nine papers met the criteria for meta-analysis—19 from
UHCSs and 10 from non-UHCSs. However, six studies that
examined receipt of treatment in low compared to high SEP
presented the results as a single OR and so could not be included
in the meta-analyses. Seventeen studies were included in the final
meta-analyses and a further six in the sensitivity meta-analyses.
Surgery
Thirty-one papers (29 study populations) included receipt of
surgery as an outcome—18 UHCS papers (15 study populations)
and 13 non-UHCS papers (14 study populations) (Tables 5 and 6).
Of the papers that reported measures of significance (CIs or p-
values), 20 out of 27 (74%) reported that lower SEP was
significantly associated with lower likelihood of surgery when
comparing the lowest with the highest SEP group, although three
of these 20 papers did not find a significant trend across groups.
Meta-analysis of all 16 populations that were suitable for
inclusion showed a significant negative effect of lower SEP on the
likelihood of receiving surgery: OR=0.72 (95% CI 0.65 to 0.80),
p,0.001, I2 = 80% (Figure S1). Including only non-overlapping
study populations (n = 12) gave a similar result: OR=0.68 (95%
CI 0.63 to 0.75), p,0.001, I2 = 53% (Figure 2). Similar results
were also seen for the subgroup of eight papers including NSCLC
Figure 2. Meta-analysis of odds of receipt of surgery in low versus high SEP. CI, confidence interval; non-UHCS, non-universal health care
system; NSCLC, non-small cell lung cancer; OR, odds ratio; SE, standard error; SEP, socioeconomic position; UHCS, universal health care system.
doi:10.1371/journal.pmed.1001376.g002
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patients only (OR=0.73 [95% CI 0.68 to 0.80] p,0.001,
I2 = 24%) (Figure S2) and with further stratification by health
care system; NSCLC (UHCS): OR=0.75 (95% CI 0.66 to 0.85),
p,0.001, I2 = 29%; NSCLC (non-UHCS, early stage only, co-
morbidity included): OR=0.71 (95% CI 0.64 to 0.78) p,0.001;
I2 = 2% (Figure 2).
Lower SEP was associated with a lower likelihood of receiving
lung cancer surgery, in both types of health care system, and in
studies where histology and stage at diagnosis were taken into
account.
Chemotherapy
Twenty-three papers included chemotherapy as an outcome—
14 UHCS papers (12 populations) and nine non-UHCS papers (10
populations) (Tables 7 and 8). Of the 21 papers that reported
measures of significance, 15 (71%) reported that lower SEP was
significantly associated with lower likelihood of receipt of
chemotherapy.
Meta-analysis of the ten populations that were suitable for
inclusion found a significant negative effect of lower SEP on the
likelihood of receiving chemotherapy: OR=0.81 (95% CI 0.73 to
0.89), p,0.001, I2 = 68% (Figure S3). Similarly, in a meta-analysis
of the eight papers containing non-overlapping populations that
were selected for inclusion, the odds of receiving chemotherapy
were significantly lower for those with low SEP compared to those
with high SEP (OR=0.82 [95% CI 0.72 to 0.93], p = 0.003,
I2 = 67%), overall. A similar pattern was found in UHCS
(OR=0.80 [95% CI 0.68 to 0.95], p = 0.01, I2 = 46%); and in
non-UHCS settings (OR=0.85 [95% CI 0.68 to 1.07], p = 0.16,
I2 = 85%), although this did not reach significance (Figure 3).
Radiotherapy
Eighteen papers (18 populations) examined receipt of radio-
therapy for lung cancer—12 in UHCS settings (11 populations)
and six in non-UHCS settings (seven populations) (Tables 9 and
10). Only one UHCS study found an association between SEP and
receipt of radiotherapy. The non-UHCS studies had very
heterogeneous outcomes.
Overall, no association between SEP and receipt of radiother-
apy was seen in the meta-analysis of the seven studies with non-
overlapping populations selected for inclusion (OR=0.99 [95%
CI 0.86 to 1.14], p = 0.89, I2 = 54%) (Figure 4), or when all nine
studies were included (OR=0.95 [95% CI 0.85 to 1.06], p = 0.40,
I2 = 71%) (Figure S4). A significant association was seen for non-
UHCS studies but only two studies were included here, each
looking at different stage patients.
Treatment Type not Specified
Seven papers (eight study populations) examined receipt of
unspecified treatment, and three papers considered receipt of
unspecified curative treatment in three populations (Tables 11–
13). In the meta-analysis of five non-overlapping studies, low SEP
was associated with a lower likelihood of receiving unspecified
treatment (OR=0.78 [95% CI 0.74 to 0.83], p,0.001, I2 = 0)
(Figure 5). This was also seen when studies with overlapping
populations were included (OR=0.80 [95% CI 0.77 to 0.84],
p,0.001, I2 = 17%) (Figure S5).
When the surgery, chemotherapy, and radiotherapy papers
included in the separate treatment meta-analyses in this systematic
review were analysed together to produce an overall summary
effect meta-analysis OR, a similar result was seen, with low SEP
associated with a lower likelihood of receiving any type of
treatment. This was found when including only studies with non-
overlapping populations (OR=0.79 [95% CI 0.73 to 0.86],
p,0.001, I2 = 77%) (Figure S6) and when including all eligible
studies (OR=0.80 [95% CI 0.75 to 0.86], p,0.001, I2 = 82%)
(Figure S7).
Figure 3. Meta-analysis of odds of receipt of chemotherapy in low versus high SEP. CI, confidence interval; non-UHCS, non-universal
health care system; OR, odds ratio; SE, standard error; SEP, socioeconomic position; UHCS, universal health care system.
doi:10.1371/journal.pmed.1001376.g003
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Discussion
Principal Findings
To our knowledge, this is the first systematic review and meta-
analysis examining socioeconomic inequalities in receipt of lung
cancer treatment. It shows an association between low SEP and
reduced likelihood of receipt of any type of treatment, surgery, and
chemotherapy. The results were generally consistent across
different health care systems.
Interpretation of Results
Surgery is suitable only for patients with early-stage NSCLC,
and it has been suggested that patients with cancer in a lower SEP
are more likely to present later and with later-stage disease [20].
This may help explain why socioeconomic inequalities in receipt of
surgery are observed in some studies. However, presentation with
later-stage cancer in lower SEP patients has not been consistently
observed [19]. In this review, when receipt of treatment was
examined in studies of early-stage patients only (from non-UHCS
studies), low SEP remained associated with reduced likelihood of
surgery. Thus, the association between SEP and receipt of surgery
appears to be independent of stage. Similar results were seen for
NSCLC studies in both health care systems.
Receipt of treatment may also be influenced by clinical
suitability for treatment, and socioeconomic differences in the
number of co-morbidities present may explain socioeconomic
inequalities in treatment. In the three UHCS studies that took co-
morbidity into account, SEP was not associated with receipt of
surgery [21,22] or of any treatment [23] when the trend across
SEP groups was examined, suggesting that co-morbidity may be a
potential mediator of socioeconomic inequalities in treatment in
UHCSs. However, most of the non-UHCS studies did include co-
morbidity as a confounder, and socioeconomic inequalities in
treatment were still observed, suggesting that there may be
differences between health care systems here.
Strengths and Weaknesses of the Review and of the
Available Evidence
This is one of the first equity reviews published [24,25], the first
systematic review of the literature on intervention-generated
inequalities in lung cancer treatment to our knowledge, and the
first cancer equity review to include a meta-analysis. Extensive
searches were carried out to identify studies. However, it is possible
that not all relevant studies were obtained.
The included studies reported observational data only. The
suitability of meta-analysis for observational studies has been
questioned, as it may produce precise but spurious results [26].
Examining the possible sources of heterogeneity by conducting
sensitivity analyses across different sub-groups may be less prone to
bias than calculating an overall summary effect [26]. Here,
although an overall summary effect OR was calculated, hetero-
geneity was taken into account. Separate analyses by type of
treatment were carried out, with further stratification by stage and
histology. Universal and non-UHCSs were examined separately
and random effects rather than fixed effects meta-analyses were
conducted. These precautions did not change the overall pattern
of results seen.
Significant heterogeneity remained in some cases, which could
be considered a limitation, although this is not surprising because
of the characteristics of the studies included. For studies examining
receipt of chemotherapy and radiotherapy it was generally not
possible to differentiate between curative and palliative treatment
and, if patterns of care differ for these by SEP, this might explain
the high degree of heterogeneity seen. However, although there is
some suggestion that heterogeneity can be considered high at
.50% [17], when confidence intervals were calculated these were
wide, so it was difficult to be confident about the degree of
heterogeneity present [27].
Results for receipt of radiotherapy differed in the non-UHCS
sub-group compared to overall but, as only two studies were
included in this sub-group, it is difficult to be sure that different
Figure 4. Meta-analysis of odds of receipt of radiotherapy in low versus high SEP. CI, confidence interval; non-UHCS, non-universal health
care system; OR, odds ratio; SE, standard error; SEP, socioeconomic position; UHCS, universal health care system.
doi:10.1371/journal.pmed.1001376.g004
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patterns of receipt of radiotherapy by SEP are due to differences in
health care system.
Many of the non-UHCS studies used overlapping population
sub-groups from the SEER database. There was also population
overlap between some UHCS datasets. We attempted to include
only substantially non-overlapping datasets within the final meta-
analyses to ensure independence of results. A judgement had to be
made as to which was the best-quality and most appropriate paper
to include, but sensitivity analyses using different inclusion
combinations (Figure S8) did not change the overall findings,
nor did including all suitable studies regardless of population
overlap (Figures S1, S3, S4, S5, S7).
Included papers contained data for patients diagnosed between
1978 and 2008. As treatment guidance has changed over time,
older studies may be less applicable to current clinical practice.
However, the majority of included studies were published within
the last five years, and sensitivity analyses excluding studies
published prior to 2000 did not change the overall findings.
Various measures of SEP were used, and these were categorised
differently—an acknowledged problem in equity reviews [28]. All
but one study measured SEP at the area level. This is a further
limitation, as area-based measures of SEP are unlikely to be
accurate markers of individual-level circumstances and access to
resources [29]. Area-based measures of SEP can be calculated using
address, making them easy to add to disease registers, such as those
used in many of the studies synthesised here. However, the reliance
on area-based markers of SEP may underestimate the strength of
the true association between SEP and receipt of treatment.
Not all studies reported details of stage and histology—both of
which influence treatment type—and very few UHCS studies took
co-morbidity into account. Thus, the ORs used in the meta-
analyses were not consistently adjusted for the same covariates.
However, we attempted to take these factors into account in the
quality scores and by conducting subgroup sensitivity analyses.
Examining only high-quality studies did not alter our findings nor
did sensitivity analyses, although consequent reduction in numbers
did result in loss of significance in some analyses, potentially due to
lack of power to detect differences.
In order to conduct meta-analysis it is necessary to compare the
odds of treatment in the lowest-SEP group with the odds in the
highest, which simplifies what may be a complex relationship across
SEP groups. However, studies that reported a change in odds ratios
across the SEP categories, and thus explored trends in receipt of
treatment, generally supported the overall findings of the review.
A number of existing tools suitable for assessing cohort study
quality were considered [15,16]. However, none of these tools was
entirely appropriate for the type of studies included and, as has
been done in previous reviews [13,30], we devised a unique tool,
adapting and utilising aspects of other available tools. This
approach has the benefit of producing a quality tool that is highly
specific for the type of studies examined.
As with any systematic review, we are unable to exclude the
possibility of publication bias. Studies reporting null findings are
less likely to be published or, if they are published, not to report
numerical outcomes [17]. A funnel plot to assess potential
publication bias did not show obvious bias (Figure S9). However,
a number of papers recovered in the search included SEP in the
description of the study population but did not report receipt of
treatment by SEP [31–34]. Study authors were contacted and
asked to provide further information, but only one supplied the
requested data [34]. It is likely that SEP was not significantly
associated with receipt of treatment in the other studies, but this
was not always clearly reported. However, publication bias is
thought to be less important than other sources of bias, such as
confounding, in meta-analyses of observational studies [26].
Implications for Policy and Practice
Socioeconomic inequalities in receipt of treatment may
exacerbate socioeconomic inequalities in incidence of lung cancer,
which is strongly associated with higher smoking rates in more
deprived populations, so may further contribute to the poorer
outcomes in lower SEP groups.
Socioeconomic inequalities in treatment may be due to
differences in access to care. Within a non-UHCS it might be
expected that socioeconomic differences in receipt of treatment
would be observed due to income-related differences in health
insurance status. Patients with lung cancer in the USA who do not
have insurance have been shown to have more limited access to
care [13]. However, as socioeconomic inequalities in receipt of
lung cancer treatment were also observed in UHCSs that do not
depend on ability to pay and in non-UHCS studies where
insurance type was taken into account, this would suggest that
other system factors may be contributing to this inequality. The
extent to which receipt of treatment is influenced by factors such as
patient choice is not known.
Variability at the patient, tumour, system, and individual
clinician levels needs to be investigated before clear recommen-
dations for changes to policy and practice can be made.
Future Research
This review has demonstrated a clear association between lower
SEP and reduced likelihood of receiving surgery, chemotherapy,
Figure 5. Meta-analysis of odds of receipt of unspecified treatment in low versus high SEP. CI, confidence interval; OR, odds ratio; SE,
standard error; SEP, socioeconomic position.
doi:10.1371/journal.pmed.1001376.g005
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and any type of unspecified treatment for lung cancer. The reasons
for these inequalities need to be more thoroughly investigated.
Better-quality UHCS studies, including statistical control for co-
morbidity and stratification by stage and histology—so that only
those patients eligible for a particular treatment are included in the
population-denominator—are required. It would also be useful to
be able to distinguish between curative and palliative intent of
treatment. In non-UHCS, studies in younger populations,
examining a range of insurance providers, are required.
Further investigation into the system and patient factors that
might contribute to socioeconomic inequalities in receipt of lung
cancer care is necessary, to help develop interventions that ensure
equitable receipt of appropriate treatment. This should include a
quantitative exploration of inequalities at each stage of the care
pathway as well as qualitative work exploring reasons for
inequality. Inequalities in receipt of treatment may contribute to
inequalities in cancer survival and so cohort survival analyses are
warranted in order to investigate intervention-generated inequal-
ities in lung cancer outcomes.
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Editors’ Summary
Background. Lung cancer is the most commonly occurring
cancer worldwide and the commonest cause of cancer-
related death. Like all cancers, lung cancer occurs when cells
begin to grow uncontrollably because of changes in their
genes. The most common trigger for these changes in lung
cancer is exposure to cigarette smoke. Most cases of lung
cancer are non-small cell lung cancer, the treatment for
which depends on the ‘‘stage’’ of the disease when it is
detected. Stage I tumors, which are confined to the lung, can
be removed surgically. Stage II tumors, which have spread to
nearby lymph nodes, are usually treated with surgery plus
chemotherapy or radiotherapy. For more advanced tumors,
which have spread throughout the chest (stage III) or
throughout the body (stage IV), surgery generally does not
help to slow tumor growth and the cancer is treated with
chemotherapy and radiotherapy. Small cell lung cancer, the
other main type of lung cancer, is nearly always treated with
chemotherapy and radiotherapy but sometimes with surgery
as well. Overall, because most lung cancers are not detected
until they are quite advanced, less than 10% of people
diagnosed with lung cancer survive for 5 years.
Why Was This Study Done? As with many other cancers,
socioeconomic inequalities have been reported for both the
incidence of and the survival from lung cancer in several
countries. It is thought that the incidence of lung cancer is
higher among people of lower socioeconomic position than
among wealthier people, in part because smoking rates are
higher in poorer populations. Similarly, it has been suggest-
ed that survival is worse among poorer people because they
tend to present with more advanced disease, which has a
worse prognosis (predicted outcome) than early disease. But
do socioeconomic inequalities in treatment exist for lung
cancer and, if they do, could these inequalities contribute to
the poor survival rates among populations of lower
socioeconomic position? In this systematic review and
meta-analysis, the researchers investigate the first of these
questions. A systematic review uses predefined criteria to
identify all the research on a given topic; a meta-analysis is a
statistical approach that combines the results of several
studies.
What Did the Researchers Do and Find? The researchers
identified 46 published papers that studied people with lung
cancer in whom receipt of treatment was reported in terms
of an indicator of socioeconomic position, such as a measure
of income or deprivation. Twenty-three of these papers were
suitable for inclusion in a meta-analysis. Lower socioeco-
nomic position was associated with a reduced likelihood of
receiving any treatment. Specifically, the odds ratio (chance)
of people in the lowest socioeconomic group receiving any
treatment was 0.79 compared to people in the highest
socioeconomic group. Lower socioeconomic position was
also associated with a reduced chance of receiving surgery
(OR = 0.68) and chemotherapy (OR= 0.82), but not radiother-
apy. The association between socioeconomic position and
surgery remained after taking cancer stage into account.
That is, when receipt of surgery was examined in early-stage
patients only, low socioeconomic position remained associ-
ated with reduced likelihood of surgery. Notably, the
association between socioeconomic position and receipt of
treatment was similar in studies undertaken in countries
where health care is free at the point of service for everyone
(for example, the UK) and in countries with primarily private
insurance health care systems (for example, the US).
What Do These Findings Mean? These findings suggest
that patients in more socioeconomically deprived circum-
stances are less likely to receive any type of treatment,
surgery, and chemotherapy (but not radiotherapy) for lung
cancer than people who are less socioeconomically
deprived. Importantly, these inequalities cannot be ex-
plained by socioeconomic differences in stage at presenta-
tion or by differences in health care system. The accuracy of
these findings may be affected by several factors. For
example, it is possible that only studies that found an
association between socioeconomic position and receipt of
treatment have been published (publication bias). More-
over, the studies identified did not include information
regarding patient preferences, which could help explain at
least some of the differences. Nevertheless, these results do
suggest that socioeconomic inequalities in receipt of
treatment may exacerbate socioeconomic inequalities in
the incidence of lung cancer and may contribute to the
observed poorer outcomes in lower socioeconomic position
groups. Further research is needed to determine the system
and patient factors that contribute to socioeconomic
inequalities in lung cancer treatment before clear recom-
mendations for changes to policy and practice can be
made.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001376.
N The US National Cancer Institute provides information
about all aspects of lung cancer for patients and health
care professionals (in English and Spanish); a monograph
entitled ‘‘Area Socioeconomic Variations in U. S. Cancer
Incidence, Mortality, Stage, Treatment, and Survival, 1975–
1999’’ is available
N Cancer Research UK also provides detailed information
about lung cancer and links to other resources, such as a
policy statement on socioeconomic inequalities in cancer
and a monograph detailing cancer and health inequalities
in the UK
N The UK National Health Service Choices website has a page
on lung cancer that includes personal stories about
diagnosis and treatment
N MedlinePlus provides links to other US sources of
information about lung cancer (in English and Spanish)
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